//www.koonmotors.com/news/health_medicine/ebola/ Ebola. Read the latest scientific and medical research on the ebola virus and its containment. en-us Mon, 16 Oct 2023 22:15:15 EDT Mon, 16 Oct 2023 22:15:15 EDT 60 //www.koonmotors.com/images/scidaily-logo-rss.png//www.koonmotors.com/news/health_medicine/ebola/ For more science news, visit ScienceDaily. //www.koonmotors.com/releases/2023/04/230425111207.htm Viruses like influenza A and Ebola invade human cells in a number of steps. Research teams investigated the final stages of viral penetration using electron tomography and computer simulations. So-called fusion pores, through which the viral genome is released into the host cell, play a central role in these processes. If they can be prevented from forming, the virus is also blocked. The Heidelberg scientists describe previously unknown mechanisms, which might lead to new approaches to prevent infections. Tue, 25 Apr 2023 11:12:07 EDT //www.koonmotors.com/releases/2023/04/230425111207.htm //www.koonmotors.com/releases/2023/01/230130130531.htm A new article shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial. The vaccine could someday be an important tool to respond to Marburg virus outbreaks. Mon, 30 Jan 2023 13:05:31 EST //www.koonmotors.com/releases/2023/01/230130130531.htm //www.koonmotors.com/releases/2022/12/221214180639.htm Two randomized, placebo-controlled trials evaluating three Ebola vaccine administration strategies in adults and children found that all the regimens were safe in both age groups, according to new results. Antibodies were produced in response to the vaccine regimens beginning at 14 days after the first vaccination and continued to be detectable at varying levels -- depending on the vaccine and regimen used -- in both children and adults for one year. The study enrolled volunteers at sites in Guinea, Liberia, Sierra Leone and Mali to identify optimal vaccination strategies to curtail outbreaks of Ebola virus disease. Wed, 14 Dec 2022 18:06:39 EST //www.koonmotors.com/releases/2022/12/221214180639.htm //www.koonmotors.com/releases/2022/06/220608112530.htm A new tool can quickly and reliably identify the presence of Ebola virus in blood samples, according to a new study. The technology, which uses so-called optical microring resonators, potentially could be developed into a rapid diagnostic test for the deadly Ebola virus disease, which kills up to 89% of infected people. Wed, 08 Jun 2022 11:25:30 EDT //www.koonmotors.com/releases/2022/06/220608112530.htm //www.koonmotors.com/releases/2022/02/220209154808.htm Scientists describe how Ebola virus, which can persist in certain areas of the body, can re-emerge to cause fatal disease -- even long after treatment with monoclonal antibodies. Wed, 09 Feb 2022 15:48:08 EST //www.koonmotors.com/releases/2022/02/220209154808.htm //www.koonmotors.com/releases/2021/09/210913220224.htm Johnson and Johnson's two-dose Ebola vaccine regimen is safe, well tolerated and produces a strong immune response in people over the age of one, according to two new articles. Mon, 13 Sep 2021 22:02:24 EDT //www.koonmotors.com/releases/2021/09/210913220224.htm //www.koonmotors.com/releases/2021/08/210802103039.htm Several proteins have been identified in hosts that interact with Ebola virus and primarily function to inhibit the production of viral genetic material in cells and prevent Ebola virus infection, according to a new study. Mon, 02 Aug 2021 10:30:39 EDT //www.koonmotors.com/releases/2021/08/210802103039.htm //www.koonmotors.com/releases/2021/07/210707112507.htm 研究人员已经发现了我复杂的细胞chanisms of Ebola virus, which could help explain its severe toll on humans and identify potential pathways to treatment and prevention. Wed, 07 Jul 2021 11:25:07 EDT //www.koonmotors.com/releases/2021/07/210707112507.htm //www.koonmotors.com/releases/2021/06/210624142318.htm Researchers have discovered a key way that one of the world's deadliest pathogens, Ebola virus, evades the immune system. Understanding this process provides new potential targets for the future development of anti-viral therapies for a disease. Thu, 24 Jun 2021 14:23:18 EDT //www.koonmotors.com/releases/2021/06/210624142318.htm //www.koonmotors.com/releases/2021/04/210416120116.htm Some survivors of ebolavirus outbreaks make antibodies that can broadly neutralize these viruses -- and now, scientists have illuminated how these antibodies can disable the viruses so effectively. The insights may be helpful for developing effective therapies. Fri, 16 Apr 2021 12:01:16 EDT //www.koonmotors.com/releases/2021/04/210416120116.htm //www.koonmotors.com/releases/2021/04/210414131945.htm A new study shows how one of Ebola virus's key proteins, VP40, uses molecular triggers in the human cell to transform itself into different tools for different jobs. Wed, 14 Apr 2021 13:19:45 EDT //www.koonmotors.com/releases/2021/04/210414131945.htm //www.koonmotors.com/releases/2021/03/210325120838.htm A new study has shown substantial benefit to combining monoclonal antibodies and the antiviral remdesivir against advanced Marburg virus. Thu, 25 Mar 2021 12:08:38 EDT //www.koonmotors.com/releases/2021/03/210325120838.htm //www.koonmotors.com/releases/2021/02/210211144244.htm Ebola is so pernicious because it pulls a fast one on the body, disguising itself as a dying cell. A study identifies a pathway that all filoviruses use to gain entry into our cells -- and shows how they can be stopped in their tracks by at least one FDA-approved drug. Thu, 11 Feb 2021 14:42:44 EST //www.koonmotors.com/releases/2021/02/210211144244.htm //www.koonmotors.com/releases/2021/02/210208134421.htm 研究人员发现了一种以前未知的年代ite on the filovirus glycoprotein to which small drug molecules can bind and prevent infection -- blocking both sites may be a more effective treatment while reducing the risk of side effects. Mon, 08 Feb 2021 13:44:21 EST //www.koonmotors.com/releases/2021/02/210208134421.htm //www.koonmotors.com/releases/2020/12/201221101155.htm Computer simulations of the Ebola virus structure are helping to crack its defenses. Ebola virus nucleocapsid stability conferred by RNA electrostatic interactions. Mon, 21 Dec 2020 10:11:55 EST //www.koonmotors.com/releases/2020/12/201221101155.htm //www.koonmotors.com/releases/2020/10/201020131355.htm As the world grapples with COVID-19, the Ebola virus is again raging. Researchers are using supercomputers to simulate the inner workings of Ebola (as well as COVID-19), looking at how molecules move, atom by atom, to carry out their functions. Now, they have revealed structural features of the Ebola virus's protein shell to provide therapeutic targets to destabilize the virus and knock it out with an antiviral treatment. Tue, 20 Oct 2020 13:13:55 EDT //www.koonmotors.com/releases/2020/10/201020131355.htm //www.koonmotors.com/releases/2020/08/200818142147.htm A new study uncovered new information on why the Ebola virus can live within bats without causing them harm, while the same virus wreaks deadly havoc to people. Tue, 18 Aug 2020 14:21:47 EDT //www.koonmotors.com/releases/2020/08/200818142147.htm //www.koonmotors.com/releases/2020/06/200610112103.htm A study has found significant differences in disease risk perception and channels of information about Ebola virus disease (EVD) in rural areas and urban centers of Guinea, West Africa. Wed, 10 Jun 2020 11:21:03 EDT //www.koonmotors.com/releases/2020/06/200610112103.htm //www.koonmotors.com/releases/2020/05/200514115734.htm The threat of a catastrophic pandemic in 2014 -- the West African Ebola outbreak -- did little to change the perception of US citizens regarding the importance of preparing for future outbreaks, say experts. Thu, 14 May 2020 11:57:34 EDT //www.koonmotors.com/releases/2020/05/200514115734.htm //www.koonmotors.com/releases/2020/04/200416135853.htm Infectious disease scientists report early development of a potential universal vaccine for Ebola viruses that preclinical tests show might neutralize all four species of these deadly viruses infecting people in recent outbreaks, mainly in Africa. Although still in early preclinical testing, researchers report that their data indicate that the prospective vaccine has potential to be a stand-alone protection from Ebola. Thu, 16 Apr 2020 13:58:53 EDT //www.koonmotors.com/releases/2020/04/200416135853.htm //www.koonmotors.com/releases/2020/03/200326124159.htm SARS-CoV-2, the virus that causes COVID-19 disease is more transmissible, but has a lower mortality rate than its sibling, SARS-CoV, according to a new review article. Thu, 26 Mar 2020 12:41:59 EDT //www.koonmotors.com/releases/2020/03/200326124159.htm //www.koonmotors.com/releases/2020/02/200212150149.htm Glioblastomas are relentless, hard-to-treat, and often lethal brain tumors. Scientists have enlisted a most unlikely ally in efforts to treat this form of cancer -- elements of the Ebola virus. Wed, 12 Feb 2020 15:01:49 EST //www.koonmotors.com/releases/2020/02/200212150149.htm //www.koonmotors.com/releases/2020/02/200206144815.htm The situation is extraordinary: there have only ever been four declarations of public health emergencies of international concern in the past and now there are two at the same time. Thu, 06 Feb 2020 14:48:15 EST //www.koonmotors.com/releases/2020/02/200206144815.htm //www.koonmotors.com/releases/2019/11/191108132426.htm 科学家已经开发出一种试验性vaccine that protected cynomolgus macaques against four types of hemorrhagic fever viruses endemic to overlapping regions in Africa. Scientists are developing and testing the candidate quadrivalent VesiculoVax vaccine. Fri, 08 Nov 2019 13:24:26 EST //www.koonmotors.com/releases/2019/11/191108132426.htm //www.koonmotors.com/releases/2019/11/191105133034.htm A new risk assessment model for the transmission of Ebola accurately predicted its spread into the Republic of Uganda, according to the researchers who developed it. Tue, 05 Nov 2019 13:30:34 EST //www.koonmotors.com/releases/2019/11/191105133034.htm //www.koonmotors.com/releases/2019/10/191024141225.htm A new study uncovered new information on why the Ebola virus can exert such catastrophic effects on the infected person. They've described for the first time how the virus disables T cells, an important line of immune defense, thus rendering the infected person less able to combat the infection. Thu, 24 Oct 2019 14:12:25 EDT //www.koonmotors.com/releases/2019/10/191024141225.htm //www.koonmotors.com/releases/2019/10/191018125510.htm A single dose of a highly diluted VSV-Ebola virus (EBOV) vaccine -- approximately one-millionth of what is in the vaccine being used to help control the ongoing Ebola outbreak in the Democratic Republic of the Congo -- remains fully protective against disease in experimentally infected monkeys, according to scientists. The investigators completed the dosage study using cynomolgus macaques and an updated vaccine component to match the EBOV Makona strain that circulated in West Africa from 2014-16. Fri, 18 Oct 2019 12:55:10 EDT //www.koonmotors.com/releases/2019/10/191018125510.htm //www.koonmotors.com/releases/2019/09/190904194458.htm In the first year after hospital discharge, mortality in Ebola survivors was five times higher than would be expected in general Guinean population (55 deaths versus 11 deaths), according to an observational study of 1,130 people. Wed, 04 Sep 2019 19:44:58 EDT //www.koonmotors.com/releases/2019/09/190904194458.htm //www.koonmotors.com/releases/2019/08/190808123847.htm Amid the worsening Ebola outbreak in the Congo, now threatening to spill into Rwanda, a new study suggests that an existing, FDA-approved drug called nitazoxanide could potentially help contain this deadly, highly contagious infection. In meticulous experiments in human cells, the drug significantly amplified immune responses to Ebola and inhibited Ebola replication. Thu, 08 Aug 2019 12:38:47 EDT //www.koonmotors.com/releases/2019/08/190808123847.htm //www.koonmotors.com/releases/2019/07/190718112449.htm Fear, trust, and the likelihood of exposure are three leading factors that influence whether people are willing to be vaccinated against a virulent disease. Thu, 18 Jul 2019 11:24:49 EDT //www.koonmotors.com/releases/2019/07/190718112449.htm //www.koonmotors.com/releases/2019/06/190613143545.htm An estimated half of Ebola virus disease outbreaks have gone undetected since it was discovered in 1976, according to new research. Although these tend to affect fewer than five patients, the study highlights the need for improved detection and rapid response, in order that outbreaks of Ebola and other public health threats are detected early and consistently. Thu, 13 Jun 2019 14:35:45 EDT //www.koonmotors.com/releases/2019/06/190613143545.htm //www.koonmotors.com/releases/2019/06/190604131223.htm Identifying vulnerabilities to outbreaks of Ebola and Lassa fever is possible following new research. This will aid government agencies and health organizations in evaluating a country's vulnerability to outbreaks, and inform decisions on strategic investments and plans. Tue, 04 Jun 2019 13:12:23 EDT //www.koonmotors.com/releases/2019/06/190604131223.htm //www.koonmotors.com/releases/2019/05/190516114552.htm Antiviral antibodies produced by survivors of Ebola infection continue to evolve and improve after recovery, according to a study of immune responses in four people who received care at Emory University Hospital in 2014. High levels of neutralizing antibodies- thought to be key to protecting someone against deadly infection -- didn't appear in patients' blood until months after they left the hospital. Thu, 16 May 2019 11:45:52 EDT //www.koonmotors.com/releases/2019/05/190516114552.htm //www.koonmotors.com/releases/2019/05/190507145516.htm In a breakthrough that could lead to a simple and inexpensive test for Ebola virus disease, researchers have generated two antibodies to the deadly virus. The antibodies, which are inexpensive to produce, potentially could be used in a simple filter paper test to detect Ebola virus and the related Marburg virus. Tue, 07 May 2019 14:55:16 EDT //www.koonmotors.com/releases/2019/05/190507145516.htm //www.koonmotors.com/releases/2019/04/190411101755.htm 医学研究人员呼吁普遍斯坦dards of care to be applied in relation to Ebola virus disease. Thu, 11 Apr 2019 10:17:55 EDT //www.koonmotors.com/releases/2019/04/190411101755.htm //www.koonmotors.com/releases/2019/03/190326132746.htm Engineers and microbiologists have developed a simple model for virus-host cell interaction driven by Ebola's adhesion to cell surface receptors. The findings could provide new information to help develop effective antiviral treatments. Tue, 26 Mar 2019 13:27:46 EDT //www.koonmotors.com/releases/2019/03/190326132746.htm //www.koonmotors.com/releases/2019/03/190306171249.htm Survivors of Ebola virus disease (EVD) in Liberia had a higher prevalence of certain health issues -- including uveitis (eye redness and pain), abdominal, chest, neurologic, and musculoskeletal abnormalities upon physical exam -- when compared to a control group of household and community members without a history of EVD, according to findings from an ongoing study. However, even participants in the control group experienced a relatively high burden of health issues overall. Wed, 06 Mar 2019 17:12:49 EST //www.koonmotors.com/releases/2019/03/190306171249.htm //www.koonmotors.com/releases/2019/02/190202171849.htm Online training has increased the knowledge of health care workers about effective prevention of Ebola up to 19 percent and reduced critical errors to 2.3 percent in a small cohort. These findings suggest that the program could improve protection of health care workers from Ebola and, because it will be easily accessible via the Internet, could be especially useful in low-resource settings. Sat, 02 Feb 2019 17:18:49 EST //www.koonmotors.com/releases/2019/02/190202171849.htm //www.koonmotors.com/releases/2019/01/190124193403.htm The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial. Eighteen healthy adults received the monoclonal antibody as part of a Phase 1 clinical trial that began in May 2018 at the NIH Clinical Center in Bethesda, Md. Thu, 24 Jan 2019 19:34:03 EST //www.koonmotors.com/releases/2019/01/190124193403.htm //www.koonmotors.com/releases/2019/01/190124095156.htm Scientists announced the first finding of Zaire ebolavirus in a bat in West Africa, adding to other evidence suggesting bats serve as a natural wildlife reservoir for Ebola and other related viruses. Thu, 24 Jan 2019 09:51:56 EST //www.koonmotors.com/releases/2019/01/190124095156.htm //www.koonmotors.com/releases/2019/01/190117090438.htm A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts. Thu, 17 Jan 2019 09:04:38 EST //www.koonmotors.com/releases/2019/01/190117090438.htm //www.koonmotors.com/releases/2019/01/190110160932.htm Scientists have developed a combination of monoclonal antibodies that protected animals from all three Ebola viruses that cause human disease. The antibody 'cocktail,' called MBP134, is the first experimental treatment to protect monkeys against Ebola virus (formerly known as Ebola Zaire), as well as Sudan virus and Bundibugyo virus, and could lead to a broadly effective therapeutic. 星期四,2019年1月10 16:09:32 EST //www.koonmotors.com/releases/2019/01/190110160932.htm //www.koonmotors.com/releases/2018/12/181214093817.htm Researchers have discovered a human protein that helps fight the Ebola virus and could one day lead to an effective therapy against the deadly disease, according to a new study. The newly discovered ability of the human protein RBBP6 to interfere with Ebola virus replication suggests new ways to fight the infection. Fri, 14 Dec 2018 09:38:17 EST //www.koonmotors.com/releases/2018/12/181214093817.htm //www.koonmotors.com/releases/2018/12/181213142125.htm Several new connections have been discovered between the proteins of the Ebola virus and human host cells, a finding that provides insight on ways to prevent the deadly Ebola virus from reproducing and could lead to novel ways to fight these lethal viral infections, according to a new study. Thu, 13 Dec 2018 14:21:25 EST //www.koonmotors.com/releases/2018/12/181213142125.htm //www.koonmotors.com/releases/2018/11/181129085538.htm Researchers have discovered that certain derivatives of amodiaquine, a medication typically used to treat malaria, could provide a new therapeutic approach to treating patients infected with Ebola virus disease by blocking the viruses from entering cells. Thu, 29 Nov 2018 08:55:38 EST //www.koonmotors.com/releases/2018/11/181129085538.htm //www.koonmotors.com/releases/2018/11/181113155150.htm Scientists have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. Study results showed that DMAbs were expressed over a wide window of time and offered complete and long-term protection against lethal virus challenges. DMAbs may also provide a novel powerful platform for rapid screening of monoclonal antibodies enhancing preclinical development. Tue, 13 Nov 2018 15:51:50 EST //www.koonmotors.com/releases/2018/11/181113155150.htm //www.koonmotors.com/releases/2018/10/181029182111.htm In the midst of an increasingly volatile Ebola outbreak in the Democratic Republic of Congo, a new study finds that the immune response generated by three experimental Ebola vaccines -- including one already deployed in the DRC -- persists for at least two and a half years. The study could have implications far beyond the Ebola fight. Mon, 29 Oct 2018 18:21:11 EDT //www.koonmotors.com/releases/2018/10/181029182111.htm //www.koonmotors.com/releases/2018/10/181011090523.htm A new Lassa fever and rabies vaccine shows lasting immunity and suggests a new way to test for protection. Thu, 11 Oct 2018 09:05:23 EDT //www.koonmotors.com/releases/2018/10/181011090523.htm //www.koonmotors.com/releases/2018/10/181010132400.htm A novel synthetic DNA vaccine developed based on technology pioneered and offers complete protection from Zaire Ebolavirus (EBOV) infection in promising preclinical research. Wed, 10 Oct 2018 13:24:00 EDT //www.koonmotors.com/releases/2018/10/181010132400.htm //www.koonmotors.com/releases/2018/10/181002082446.htm A new study used text message surveys to determine in real time how people used maternal health services during a recent Ebola outbreak and measured a drop in hospital-based births during the outbreak. Tue, 02 Oct 2018 08:24:46 EDT //www.koonmotors.com/releases/2018/10/181002082446.htm //www.koonmotors.com/releases/2018/09/180912202410.htm Two new studies are bringing Ebola virus's weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection -- not only for Ebola virus, but for other closely related pathogens as well. Wed, 12 Sep 2018 20:24:10 EDT //www.koonmotors.com/releases/2018/09/180912202410.htm //www.koonmotors.com/releases/2018/08/180830180111.htm New research elucidates the mechanism of sexual transmission of filoviruses, which have been shown to persist in the testes and other immune privileged sites. Sexual transmission of filoviruses was first reported in 1968 after an outbreak of Marburg virus disease and recently caused flare-ups of Ebola virus disease in the 2013-2016 outbreak. The team found that Marburg virus persists in seminiferous tubules and that Sertoli cells are the reservoir for the virus. Thu, 30 Aug 2018 18:01:11 EDT //www.koonmotors.com/releases/2018/08/180830180111.htm //www.koonmotors.com/releases/2018/08/180823141027.htm 'The current approach for treatment of filovirus infections with antibody cocktails tested in animal models utilizes the principle of targeting of non-overlapping epitopes. Our study suggests that possible synergistic effects of antibodies which block various steps of viral replication should be also considered.' Thu, 23 Aug 2018 14:10:27 EDT //www.koonmotors.com/releases/2018/08/180823141027.htm //www.koonmotors.com/releases/2018/08/180823092101.htm The Central Africa region is experiencing rapid urbanization, economic growth and infrastructure development. These changes, while generally positive, also make the region more vulnerable to infectious disease outbreaks. Efforts to build up the health care infrastructure in Central Africa are critically needed to mitigate or prevent a large outbreak of Ebola or other infectious disease in the region. Thu, 23 Aug 2018 09:21:01 EDT //www.koonmotors.com/releases/2018/08/180823092101.htm //www.koonmotors.com/releases/2018/08/180810195146.htm Despite promising advances, important scientific questions remain unanswered in the effort to develop a safe and effective Ebola vaccine, according to members of an international Ebola research consortium. The experts now review the current field of Ebola vaccine candidates and clinical trials and highlight key gaps in knowledge that need to be addressed by future research. Fri, 10 Aug 2018 19:51:46 EDT //www.koonmotors.com/releases/2018/08/180810195146.htm //www.koonmotors.com/releases/2018/08/180809175109.htm A one-two punch of powerful antibodies may be the best way to stop Ebola virus, reports an international team of scientists. Thu, 09 Aug 2018 17:51:09 EDT //www.koonmotors.com/releases/2018/08/180809175109.htm //www.koonmotors.com/releases/2018/08/180808075247.htm A new study is shedding light on the role of specific proteins that trigger a mechanism allowing Ebola virus to enter cells to establish replication. Wed, 08 Aug 2018 07:52:47 EDT //www.koonmotors.com/releases/2018/08/180808075247.htm //www.koonmotors.com/releases/2018/07/180730154724.htm Researchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans. Mon, 30 Jul 2018 15:47:24 EDT //www.koonmotors.com/releases/2018/07/180730154724.htm //www.koonmotors.com/releases/2018/07/180717142540.htm Recent Ebola virus disease (EVD) outbreaks highlight the need for licensed treatments. ZMapp, an experimental therapy, has shown promise in a clinical trial, but targets only one of five known species of Ebola virus. Now scientists have discovered powerful, broadly neutralizing antibodies (bNAbs) in the blood of EVD survivors. In animal studies, two of these antibodies provided substantial protection against disease caused by the three species known to cause fatal human illness. Tue, 17 Jul 2018 14:25:40 EDT //www.koonmotors.com/releases/2018/07/180717142540.htm //www.koonmotors.com/releases/2018/07/180711122414.htm Researchers have shed new light on the psychiatric and neurological problems that Ebola survivors can suffer from, and call for more specialist support for the most severely affected patients. Wed, 11 Jul 2018 12:24:14 EDT //www.koonmotors.com/releases/2018/07/180711122414.htm